Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MACE Clear all
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 8, 2026, 7:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
242
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Terminated Phase 1 Interventional

Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

NCT00868855
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen

NCT05821309
View directory record Official record
Conditions
Constipation
Interventions
PEG 3350, PEG-3350 with electrolytes, Glycerin
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

NCT04195139
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nivolumab, Temozolomide
Drug
Lead sponsor
University of Sydney
Other
Eligibility
65 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 8, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 8, 2026, 7:06 AM EDT
Completed No phase listed Observational

Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

NCT04568083
View directory record Official record
Conditions
Myocardial Infarction (MI)
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Up to 130 Years
Enrollment
7,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 8, 2026, 7:06 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

NCT03518034
View directory record Official record
Conditions
Hypogonadism, Cardiovascular Diseases
Interventions
AndroGel®, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
5,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
379
States / cities
Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 8, 2026, 7:06 AM EDT
Completed No phase listed Observational

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

NCT00998127
View directory record Official record
Conditions
Medication Non-adherence, Stent Thrombosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
5,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 8, 2026, 7:06 AM EDT
Terminated Phase 4 Interventional Results available

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

NCT05038878
View directory record Official record
Conditions
Mild Autonomous Cortisol Excess
Interventions
Elagolix
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 8, 2026, 7:06 AM EDT
Withdrawn No phase listed Observational

MACE CDS Software Master Enrollment Protocol

NCT06257628
View directory record Official record
Conditions
Cardiac Events
Interventions
Index Event
Device
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
23 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 8, 2026, 7:06 AM EDT
Active, not recruiting Phase 4 Interventional

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

NCT06098079
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone-Bupropion (NB) Combination, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
140
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Clinical and Personal Information Shape Physicians' Risk Judgments

NCT07162376
View directory record Official record
Conditions
Major Adverse Cardiac Event (MACE)
Interventions
Personal Information Disclosure
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 8, 2026, 7:06 AM EDT
Completed No phase listed Observational

Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes

NCT06851325
View directory record Official record
Conditions
STEMI, Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years to 79 Years
Enrollment
6,180 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

NCT05605964
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprolide Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
108
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Recruiting No phase listed Observational

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

NCT03720613
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Lubiprostone, Naloxegol
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
34,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 8, 2026, 7:06 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Recombinant Influenza Vaccination in U.S. Nursing Homes

NCT03965195
View directory record Official record
Conditions
Influenza, Influenza -Like Illness, Influenza, Human
Interventions
Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 8, 2026, 7:06 AM EDT
Completed No phase listed Observational

Impact of OSA on Outcomes in Acute Coronary Syndrome

NCT03793582
View directory record Official record
Conditions
OSA, ACS - Acute Coronary Syndrome, Major Adverse Cardiac Events
Interventions
ApneaLink Type III portable sleep study
Diagnostic Test
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 8, 2026, 7:06 AM EDT
Recruiting No phase listed Observational

Tezspire Cardiac Events PASS

NCT06951867
View directory record Official record
Conditions
Cardiovascular Events, MACE
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
16,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 8, 2026, 7:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event

NCT01832714
View directory record Official record
Conditions
Concussion, Mild, Concussion, Intermediate, Concussion, Severe
Interventions
Not listed
Lead sponsor
Neurolign
Industry
Eligibility
19 Years to 45 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 8, 2026, 7:06 AM EDT
Completed No phase listed Observational Results available

Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit

NCT00927160
View directory record Official record
Conditions
Model of Care for Hospitalized Older Adults
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
75 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 8, 2026, 7:06 AM EDT
Completed Phase 2 Interventional

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

NCT00116012
View directory record Official record
Conditions
Coronary Disease
Interventions
rNAPc2
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Sep 8, 2026, 7:06 AM EDT
Completed No phase listed Observational Results available

Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)

NCT01930214
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Little Rock, Arkansas • Glendale, California • Hartford, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 8, 2026, 7:06 AM EDT